Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
115M
-
Number of holders
-
163
-
Total 13F shares, excl. options
-
78.4M
-
Shares change
-
-216K
-
Total reported value, excl. options
-
$536M
-
Value change
-
-$2.03M
-
Put/Call ratio
-
0.49
-
Number of buys
-
66
-
Number of sells
-
-82
-
Price
-
$6.84
Significant Holders of Coherus Oncology, Inc. - Common Stock (CHRS) as of Q1 2023
190 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock as of Q1 2023.
Coherus Oncology, Inc. - Common Stock (CHRS) has 163 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 78.4M shares
of 115M outstanding shares and own 67.95% of the company stock.
Largest 10 shareholders include BlackRock Inc. (14.4M shares), Temasek Holdings (Private) Ltd (7.38M shares), ALLIANCEBERNSTEIN L.P. (6.14M shares), STATE STREET CORP (6.1M shares), JPMORGAN CHASE & CO (5.98M shares), VANGUARD GROUP INC (5.86M shares), Kohlberg Kravis Roberts & Co. L.P. (3.04M shares), Aristotle Capital Boston, LLC (2.25M shares), CITADEL ADVISORS LLC (1.5M shares), and AMERIPRISE FINANCIAL INC (1.37M shares).
This table shows the top 163 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.